Literature DB >> 32930787

Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.

Andrew L Lin1,2,3, Mark T A Donoghue4, Sharon L Wardlaw5, T Jonathan Yang6, Lisa Bodei7, Viviane Tabar2,3,8, Eliza B Geer2,3,9.   

Abstract

A small subset of pituitary adenomas grows despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in the treatment of pituitary tumors is the alkylating agent temozolomide. At most, 50% of patients exhibit an objective response to temozolomide and the median time to progression is short; thus, there remains a significant unmet need for effective treatments within this patient population. Several targeted agents have reported activity in this tumor type-including small molecule inhibitors, checkpoint inhibitors, and other biologics-but remain investigational at this time.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  aggressive pituitary adenoma; pituitary carcinoma; temozolomide

Mesh:

Year:  2020        PMID: 32930787      PMCID: PMC7566322          DOI: 10.1210/clinem/dgaa649

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  104 in total

1.  111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.

Authors:  Thomas A Hope; Jeremie Calais; Li Zhang; William Dieckmann; Corina Millo
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

2.  Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.

Authors:  Hanna R Kemeny; Aladine A Elsamadicy; S Harrison Farber; Cosette D Champion; Selena J Lorrey; Pakawat Chongsathidkiet; Karolina I Woroniecka; Xiuyu Cui; Steven H Shen; Kristen E Rhodin; Vadim Tsvankin; Jeffrey Everitt; Luis Sanchez-Perez; Patrick Healy; Roger E McLendon; Patrick J Codd; Ian F Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2019-11-19       Impact factor: 12.531

3.  High-resolution(18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease.

Authors:  Prashant Chittiboina; Blake K Montgomery; Corina Millo; Peter Herscovitch; Russell R Lonser
Journal:  J Neurosurg       Date:  2014-12-05       Impact factor: 5.115

Review 4.  Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature.

Authors:  Rita E Landman; Melvin Horwith; Ralph E Peterson; Alexander G Khandji; Sharon L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 5.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

6.  Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases.

Authors:  Federico Roncaroli; Vania Nosé; Bernd W Scheithauer; Kalman Kovacs; Eva Horvath; William F Young; Ricardo V Lloyd; Mari C Bishop; Bradley Hsi; Jonathan A Fletcher
Journal:  J Neurosurg       Date:  2003-08       Impact factor: 5.115

7.  Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Authors:  Andrew L Lin; Philip Jonsson; Viviane Tabar; T Jonathan Yang; John Cuaron; Katherine Beal; Marc Cohen; Michael Postow; Marc Rosenblum; Jinru Shia; Lisa M DeAngelis; Barry S Taylor; Robert J Young; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

8.  A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides.

Authors:  F E Kaiser; D N Orth; K Mukai; J H Oppenheimer
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

9.  Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Authors:  Deborah T Blumenthal; Thierry Gorlia; Mark R Gilbert; Michelle M Kim; L Burt Nabors; Warren P Mason; Monika E Hegi; Peixin Zhang; Vassilis Golfinopoulos; James R Perry; Do Hyun Nam; Sara C Erridge; Benjamin W Corn; René O Mirimanoff; Paul D Brown; Brigitta G Baumert; Minesh P Mehta; Martin J van den Bent; David A Reardon; Michael Weller; Roger Stupp
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

10.  Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.

Authors:  Norbert Chauvet; Nicola Romanò; Chrystel Lafont; Anne Guillou; Evelyne Galibert; Xavier Bonnefont; Paul Le Tissier; Monica Fedele; Alfredo Fusco; Patrice Mollard; Nathalie Coutry
Journal:  Int J Cancer       Date:  2017-02-14       Impact factor: 7.396

View more
  8 in total

Review 1.  Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.

Authors:  Ding Nie; Yimeng Xue; Qiuyue Fang; Jianhua Cheng; Bin Li; Dawei Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  Dis Markers       Date:  2021-08-16       Impact factor: 3.434

2.  Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.

Authors:  Andrew L Lin; Viviane Tabar; Robert J Young; Marc Cohen; John Cuaron; T Jonathan Yang; Marc Rosenblum; Vasilisa A Rudneva; Eliza B Geer; Lisa Bodei
Journal:  J Endocr Soc       Date:  2021-08-07

3.  The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.

Authors:  Zhiyu Xi; Pamela S Jones; Masaaki Mikamoto; Xiaobin Jiang; Alexander T Faje; Chuansheng Nie; Kathryn E Labelle; Yunli Zhou; Karen K Miller; Roy J Soberman; Xun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-21       Impact factor: 5.555

4.  A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors.

Authors:  Jie Cui; Jianbo Shen; Xiaohong Ru; Zhihua Tian; Zhibin Duan; Guiping Chen; Min Li
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375

5.  Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.

Authors:  Oriol Mirallas; Francesca Filippi-Arriaga; Irene Hernandez Hernandez; Anton Aubanell; Anas Chaachou; Alejandro Garcia-Alvarez; Jorge Hernando; Elena Martínez-Saez; Betina Biagetti; Jaume Capdevila
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

6.  Editorial: Resistance to Medical Therapy in Pituitary Tumors.

Authors:  Renata S Auriemma; Manuel D Gahete; Federico Gatto
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-23       Impact factor: 5.555

7.  PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling.

Authors:  Jingdian Liu; Junwen Wang; Weidong Tian; Yu Xu; Ran Li; Kai Zhao; Chao You; Yuan Zhu; Joerg Walter Bartsch; Hongquan Niu; Huaqiu Zhang; Kai Shu; Ting Lei
Journal:  Aging (Albany NY)       Date:  2022-08-11       Impact factor: 5.955

Review 8.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.